Page 84 - Clinical Development News Today

Qunaterix' LucentAD test could reveal whether a person is likely to have Alzheimer's Disease or not. In an interview with company CEO, Masoud Toloue, he explains the science and motivation behind the test.

Late-breaking data presented at 9th ESWI Influenza Conference in Valencia ...

In a study that did not achieve its recruitment goal, the patients who benefited most from the vaccine had previously responded to immunotherapy.

/PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a biotechnology company focused on...

S E P T E M B E R 2 0 2 3 Investor Day September 14, 2023 ©2023 Laboratory...

Qunaterix' LucentAD test could reveal whether a person is likely to have Alzheimer's Disease or not. In an interview with company CEO, Masoud Toloue, he explains the science and motivation behind the test.

An advanced wearable headband with integrated machine learning algorithms has achieved The US Food and Drug Administration’s 510(k) clearance.

The Japanese firm Astellas Pharma will apply for planning permission to construct a drug manufacturing facility in Tralee, Co. Kerry, Ireland worth around €330 million ($352 million).

The small molecule drug Ojjaara (momelotinib), developed by GlaxoSmithKline, has become the first U.S. Food and Drug Administration (FDA)-approved treatment for patients with the blood cancer myelofibrosis and anemia.

Andrew MacGarvey is chief operating officer (COO) of Phastar. We caught up with him earlier in the summer at DIA Global in Boston to discuss the company’s origins, opportunities for big analytical data DCTs, artificial intelligence and machine learning among many other topics.